These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 28657404)
1. New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system. Gülbağ S; Yılmaz Usta D; Gültekin HE; Oktay AN; Demirtaş Ö; Karaküçük A; Çelebi N Pharm Dev Technol; 2018 Jun; 23(5):512-519. PubMed ID: 28657404 [TBL] [Abstract][Full Text] [Related]
2. Application of SeDeM expert systems in preformulation studies of pediatric ibuprofen ODT tablets. Sipos E; Oltean AR; Szabó ZI; Rédai EM; Nagy GD Acta Pharm; 2017 Jun; 67(2):237-246. PubMed ID: 28590910 [TBL] [Abstract][Full Text] [Related]
3. Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system. Aguilar-Díaz JE; García-Montoya E; Suñe-Negre JM; Pérez-Lozano P; Miñarro M; Ticó JR Eur J Pharm Biopharm; 2012 Apr; 80(3):638-48. PubMed ID: 22245156 [TBL] [Abstract][Full Text] [Related]
4. Assessing disintegration effectiveness: A thorough evaluation using the SeDeM-ODT expert system for doxylamine succinate orodispersible formulation. Ahmad SA; Hasan SMF; Bafail D; Shah SF; Imran M; Sahar T; Ishaqui AA PLoS One; 2024; 19(9):e0310334. PubMed ID: 39288134 [TBL] [Abstract][Full Text] [Related]
5. Development of multiple-unit pellet system tablets by employing the SeDeM expert diagram system II: pellets containing different active pharmaceutical ingredients. Hamman H; Hamman J; Wessels A; Scholtz J; Steenekamp J Pharm Dev Technol; 2019 Feb; 24(2):145-156. PubMed ID: 29394129 [TBL] [Abstract][Full Text] [Related]
6. SeDeM Expert System, an Innovative Tool for Developing Directly Compressible Tablets: A Review. Singh I; Thakur AK; Bala R; Madan R Curr Drug Res Rev; 2021; 13(1):16-24. PubMed ID: 32988362 [TBL] [Abstract][Full Text] [Related]
7. Development of multiple-unit pellet system tablets by employing the SeDeM expert diagram system I: pellets with different sizes. Hamman H; Hamman J; Wessels A; Scholtz J; Steenekamp JH Pharm Dev Technol; 2018 Sep; 23(7):706-714. PubMed ID: 28612663 [TBL] [Abstract][Full Text] [Related]
8. The use of the SeDeM diagram expert system for the formulation of Captopril SR matrix tablets by direct compression. Saurí J; Millán D; Suñé-Negre JM; Pérez-Lozano P; Sarrate R; Fàbregas A; Carrillo C; Miñarro M; Ticó JR; García-Montoya E Int J Pharm; 2014 Jan; 461(1-2):38-45. PubMed ID: 24284019 [TBL] [Abstract][Full Text] [Related]
9. The use of the SeDeM Diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT. Aguilar-Díaz JE; García-Montoya E; Pérez-Lozano P; Suñe-Negre JM; Miñarro M; Ticó JR Eur J Pharm Biopharm; 2009 Nov; 73(3):414-23. PubMed ID: 19602435 [TBL] [Abstract][Full Text] [Related]
10. Optimization of the process variables of roller compaction, on the basis of granules characteristics (flow, mechanical strength, and disintegration behavior): an application of SeDeM-ODT expert system. Khan A Drug Dev Ind Pharm; 2019 Sep; 45(9):1537-1546. PubMed ID: 31210544 [TBL] [Abstract][Full Text] [Related]
11. Pharmacotechnical Evaluation by SeDeM Expert System to Develop Orodispersible Tablets. Rao MRP; Sapate S; Sonawane A AAPS PharmSciTech; 2022 May; 23(5):133. PubMed ID: 35534652 [TBL] [Abstract][Full Text] [Related]
12. Formulation of Direct Compression Zidovudine Tablets to Correlate the SeDeM Diagram Expert System and the Rotary Press Simulator Styl'ONE Results. Nofrerias I; Nardi A; Suñé-Pou M; Suñé-Negre JM; García-Montoya E; Pérez-Lozano P; Miñarro M; Bataille B; Ticó JR AAPS PharmSciTech; 2019 Nov; 21(1):1. PubMed ID: 31712905 [TBL] [Abstract][Full Text] [Related]
13. Prediction of quality attributes (mechanical strength, disintegration behavior and drug release) of tablets on the basis of characteristics of granules prepared by high shear wet granulation. Khan A PLoS One; 2021; 16(12):e0261051. PubMed ID: 34882723 [TBL] [Abstract][Full Text] [Related]
14. Formulation studies for mirtazapine orally disintegrating tablets. Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146 [TBL] [Abstract][Full Text] [Related]
15. Application of the SeDeM Expert System in Studies for Direct Compression Suitability on Mixture of Rhodiola Extract and an Excipient. Wan S; Yang R; Zhang H; Li X; Gu M; Guan T; Ren J; Sun H; Dai C AAPS PharmSciTech; 2019 Feb; 20(3):105. PubMed ID: 30746569 [TBL] [Abstract][Full Text] [Related]
16. Application of SeDeM Expert system in formulation development of effervescent tablets by direct compression. Khan A; Iqbal Z; Rehman Z; Nasir F; Khan A; Ismail M; Roohullah ; Mohammad A Saudi Pharm J; 2014 Nov; 22(5):433-44. PubMed ID: 25473332 [TBL] [Abstract][Full Text] [Related]
17. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method. Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500 [TBL] [Abstract][Full Text] [Related]
18. Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet. Hazdi SN; Phang HC; Ng ZQ; Chew YL; Uddin AH; Sarker ZI; Lee SK; Liew KB Int J Pharm Compd; 2023; 27(6):522-527. PubMed ID: 38100670 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets. Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637 [TBL] [Abstract][Full Text] [Related]
20. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs). Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]